Analysis Of Income And Expense [Abstract]

Bayer AG - Filing #6464694

Concept	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	46,606,000 EUR	47,637,000 EUR
Material income and expense [abstract]
Research and development expense	6,209,000 EUR	5,371,000 EUR
Finance income (cost)	—	—
Other finance income (cost)	2,263,000 EUR	2,233,000 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	1,396,000 EUR	663,000,000 EUR
Other comprehensive income, attributable to owners of parent	1,594,000 EUR	483,000,000 EUR
Other comprehensive income, attributable to non-controlling interests	3,000,000 EUR	2,000,000 EUR
Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract]
Share of profit (loss) of associates and joint ventures accounted for using equity method	132,000,000 EUR	162,000,000 EUR
Share of other comprehensive income of associates and joint ventures accounted for using equity method, net of tax [abstract]
Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax	8,000,000 EUR	2,000,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	949,000,000 EUR	3,427,000 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	958,000,000 EUR	3,424,000 EUR
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests	9,000,000 EUR	3,000,000 EUR